Clinical trial comparing benralizumab and mepolizumab subcutaneous immunotherapies for managing vasculitis with oral corticosteroid tapering.

Patentradars sammanfattning

This is a randomized, double-blind clinical study comparing two monoclonal antibody therapies—benralizumab and mepolizumab—administered via subcutaneous injection every 4 weeks. Patients must have stable oral corticosteroid (OCS) dosing for at least 4 weeks before baseline, with OCS tapering permitted from week 4 onward if Birmingham Vasculitis Activity Score (BVAS) equals zero. The trial includes a double-blind phase followed by an open-label extension, with efficacy and safety assessed through multiple visits spanning 52 weeks.

AI-genererad och redaktionellt processad.